In this issue:
High field MRI for MS diagnosis
Fingolimod vs dimethyl fumarate in multiple sclerosis
Clinical activity after fingolimod cessation: disease reactivation or rebound?
Early versus later treatment start in multiple sclerosis
Effects of MS disease-modifying therapies on employment measures
Smoking and worsening disability in multiple sclerosis
Sex ratio in MS mortality over 65 years
Two-year real-life efficacy, tolerability and safety of dimethyl fumarate
Alemtuzumab as rescue therapy in RRMS patients with breakthrough disease on fingolimod
Plasma neurofilament light chain levels as a biomarker of MS therapy response
Please login below to download this issue (PDF)